A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494

Status	RECRUITING
Sponsor	Ascendis Pharma A/S
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (3)

- Participants aged 15 to 50 years
- Participants with exposure to at least one dose of YORVIPATH at any time within 15 days prior to conception and/or during pregnancy. The timeframe of 15 days prior to conception is calculated based on 5 times the YORVIPATH half life of \~ 60 hours
- Participants providing written informed consent, verbal consent, or eConsent (depending on country regulations) and a Medical Release of Information. For adolescents under the age of majority, verbal or written informed assent by the pregnant minor (where applicable) and verbal or written informed consent by the parent/legal guardian will be obtained.

Exclusion (1)

- Pregnancies in which only the male partner is exposed to at least one dose of YORVIPATH.

Locations (1 total)

Ascendis Investigational Site, Morgantown, West Virginia, United States